| Symbol | OBIO |
|---|---|
| Name | ORCHESTRA BIOMED HOLDINGS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medicinal Chemicals and Botanical Products |
| Address | 150 UNION SQUARE DRIVE, NEW HOPE, Pennsylvania, 18938, United States |
| Telephone | +1 215 - 862-5797 |
| Fax | — |
| — | |
| Website | https://www.orchestrabiomed.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001814114 |
| Description | Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. It is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant. Additional info from NASDAQ: |
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
Read moreDirector Pacitti David 🔴 sold 3.8K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.42 Transaction Date: Aug 12, 2026 | Filing ID: 097195
Read moreDirector Mack John Prosper 🔴 sold 4.9K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.42 Transaction Date: Aug 12, 2026 | Filing ID: 097183
Read moreOrchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Read more📋 Sherman Darren (Officer) plans to sell 15K shares of Orchestra BioMed Holdings, Inc. (at $4.09 each, total $61K) Filed: Aug 03, 2026 | ID: 005567
Read moreDirector Sherman Darren 🔴 sold 15.0K shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.27 Transaction Date: Jul 01, 2026 | Filing ID: 080333
Read more📋 Sherman Darren (Officer) plans to sell 15K shares of Orchestra BioMed Holdings, Inc. (at $4.32 each, total $65K) Filed: Jul 01, 2026 | ID: 005000
Read moreDirector Fain Eric S 🟡 adjusted position in 34.3K shares (1 derivative) of Orchestra BioMed Holdings, Inc. (OBIO) at $4.04 Transaction Date: Jun 23, 2026 | Filing ID: 077780
Read moreDirector Pacitti David 🟡 adjusted position in 34.8K shares (1 derivative) of Orchestra BioMed Holdings, Inc. (OBIO) at $4.04 Transaction Date: Jun 23, 2026 | Filing ID: 077778
Read more